Carbidopa Levodopa Tablets Recall: Blister Packaging Defect
The Harvard Drug Group recalls Carbidopa and Levodopa tablets due to blister packaging that may not seal properly. This could lead to medication exposure risks for patients using prescription medication.
Lower-risk recall
Packaging defect: observed packaging defect, blister packaging inadequately sealed.
Contact the company
What happened, in plain English
The Harvard Drug Group is recalling Carbidopa and Levodopa tablets (25 mg/100 mg) because the blister packaging may not seal properly. This defect could expose the medication to air or moisture, potentially affecting its safety and effectiveness for patients using these prescription drugs. Read more at govinfonow.com/recall/33853-carbidopa-levodopa-tablets-recall-blister-packaging-defect.
Source Summary by GovInfoNow · govinfonow.com/recall/33853-carbidopa-levodopa-tablets-recall-blister-packaging-defect · Updated August 18, 2026 · FDA enforcement record: FDA #D-0432-2023
Cite this page
“Carbidopa Levodopa Tablets Recall: Blister Packaging Defect.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/33853-carbidopa-levodopa-tablets-recall-blister-packaging-defect. Based on FDA recall #D-0432-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0432-2023%22&limit=1).
Why it’s dangerous
The blister packaging may not seal properly, which could allow the medication to be exposed to air or moisture. This might affect the medication's stability and effectiveness, but it does not pose an immediate risk of injury or serious harm.
Who’s affected
Patients prescribed Carbidopa and Levodopa tablets by a doctor. Those using the medication for Parkinson's disease or other conditions are most at risk.
How to tell if you have this one
Check for the product name 'Carbidopa and Levodopa Tablets, USP 25 mg/100 mg', 10x10 Unit Dose carton, Rx Only. The lot number M04145 with an expiration date of January 2024.
- Brand
The Harvard Drug Group- Product
Carbidopa and Levodopa Tablets, USP 25 mg/100 mg, 10x10 Unit Dose carton, Rx Only, Manufactured in Czech Republic by- Category
Drug
What to do — step by step
Check Medication Packaging
Look for the lot number M04145 and expiration date of January 2024 on the packaging.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Distributed Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 14 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0432-2023 (February 23, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0432-2023 to see it in context.
- Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.